Consolidated Q4/ 2019 Q4/ 2018 Change Financial Statements (Million Baht) (%) (Million Baht) (%) (%) Revenue from Sales 1,416.8 100.0 % 1,402.5 100.0 % 1.0 % Cost of Sales (984.1) (69.5 %) (1,031.2) (73.5
as follow: Consolidated Q2/ 2020 Q2/ 2019 Change Financial Statements (Million Baht) (%) (Million Baht) (%) (%) Revenue from Sales 1,011.6 100.0 % 1,302.1 100.0 % (22.3 %) Cost of Sales (734.6) (72.6
, The Company’s strategies such as increasing more specialty cilinics, medical instruments and expanding into new market so as to drive a sustainable growth Cost of Hospital Operations The costs of
30.69 1.90 6.21 Total revenue 1,151,091 1,374,128 (223,037) (16.23) 2,970,715 2,646,863 323,852 12.24 Total Cost & Expenses 1,013,853 1,243,461 (229,608) (18.47) 2,699,583 2,466,406 233,177 9.45 Selling
. Rathian Srimongkol as the Vice Chairman of the Board of Directors, effective from 12 October 2018. Appointed Prof. Dr. Surakiat Sathirathai as the Chairman of the Board of Directors and appointed Mr. Lee
record high depreciation cost in full which did not correspond to such low utilization of production and machinery. The Company engaged independent engineering expert to inspect and appraise the assets and
other expenses were 2,035 million baht, increased by 112 million baht or 6% y-y due to increase of advertising expense 55% y-y. However, the Company still maintained effective operating cost control with
88 million baht or 5% y-y and 3% q-q. However, the Company still maintained effective operating cost control with cost to income ratio at 35% of total revenues. Considering the Company’s separate
high profit margin and also from effective marketing policy. (2) Analysis of Operating Results and Profitability (2.1) Revenues from Sales and Services Description Year 2018 Year 2017 Increase
construction under a concession arrangement 131.3 398.1 215.0 126.1 (88.9) (41.3%) 104.6 870.5 765.9 732.2% Cost of sales and services (788.7) (796.3) (822.9) (788.4) (34.5) (4.2%) (3,324.7) (3,196.3) (128.4